PD14-05 ECONOMIC IMPLICATIONS OF UROLOGIST PRESCRIPTION PRACTICES AMONG MEDICARE PART D BENEFICIARIES

• DOI: 10.1016/j.juro.2017.02.706
• Publication Date: 2017-04-03T18:17:13Z
• Authors: Peter Kirk; Tudor Borza; James Dupree; John Wei; Chad Ellimoottil; Megan Caram; Brent Hollenbeck; Ted Skolarus
• Keywords: 03 medical and health sciences; 0302 clinical medicine

You have accessJournal of UrologyGeneral & Epidemiological Trends Socioeconomics: Value Care: Cost and Outcomes Measures I1 Apr 2017PD14-05 ECONOMIC IMPLICATIONS OF UROLOGIST PRESCRIPTION PRACTICES AMONG MEDICARE PART D BENEFICIARIES Peter Kirk, Tudor Borza, James Dupree, John Wei, Chad Ellimoottil, Megan Caram, Brent Hollenbeck, Ted Skolarus KirkPeter Kirk More articles by this author , BorzaTudor Borza DupreeJames Dupree WeiJohn Wei EllimoottilChad Ellimoottil CaramMegan Caram HollenbeckBrent Hollenbeck SkolarusTed View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.706AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Millions patients take prescription medications each year for common urologic conditions. Generic brand name drugs often widely divergent pricing despite similar therapeutic benefit side effect profiles. Because prescriptions will only increase as the US population ages, we examined urologist patterns generic used treat three conditions, consequent economic implications Medicare Part spending. METHODS We extracted all 2014 claims payments from Prescriber Public Use File. categorized oral urological conditions: benign prostate enlargement, erectile dysfunction, overactive bladder. then total claims, payments, 30 day cost medication with at least 1,000 claims. Last, estimated excess annual associated use non higher medications. selected a low and/or drug comparator class, calculated difference between actual equivalent length comparator. RESULTS The condition are shown (Table). Within payment other than tamsulosin or finasteride was $158,935,926. Among dysfunction medications, Levitra $3,105,023. bladder, oxybutynin extended-release $248,430,484. prescribed urologists in $410,471,433. CONCLUSIONS beneficiaries, found conditions approached half billion dollars. Increasing where available evidence is equivocal represents promising policy target reduce © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e278 Advertisement Copyright Permissions© 2017MetricsAuthor Information Expand PDF downloadLoading ...